Collegium Pharmaceutical, Inc. COLL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.5M-14.5% | $16.96M-46.2% | $31.51M+163% | $11.98M+396% | $2.42M-80.7% | ||
| $463K-49.8% | $923K-10.6% | $1.03M-9.0% | $1.14M+4.0% | $1.09M+4.8% | ||
| $10.88M+11.6% | $9.75M-0.6% | $9.81M-9.3% | $10.82M-6.1% | $11.52M+51.7% | ||
| -$968K+90.4% | -$10.07M+17.0% | -$12.13M-316% | -$2.91M-441% | -$539K+94.7% | ||
| $819K-35.8% | $1.28M-5.0% | $1.34M-0.9% | $1.36M-0.9% | $1.37M-4.0% | ||
| $17.43M+177% | -$22.62M-208% | $20.93M+233% | -$15.68M-9,323% | $170K— | ||
| $1.83M-36.1% | $2.86M— | $0-100% | $930K-43.9% | $1.66M+167% | ||
| -$3.83M-226% | $3.05M— | —— | —— | $13.92M— | ||
| -$4.15M— | —— | -$8.11M— | —— | -$17.67M— | ||
| -$4.13M-150% | $8.19M+138% | -$21.34M-297% | $10.85M+5.6% | $10.27M+427% | ||
| -$167K0.0% | -$167K— | —— | —— | $0— | ||
| $55.47M— | —— | —— | —— | $55.47M0.0% | ||
| $0+100% | -$19K0.0% | -$19K+94.7% | -$358K+54.5% | -$786K+73.0% | ||
| $57.11M-53.6% | $123.05M+56.9% | $78.44M+8.3% | $72.44M+30.8% | $55.4M-34.6% | ||
| $270K-60.8% | $689K+266% | $188K+189% | $65K-91.9% | $798K+40.0% | ||
| $1.63M+108% | -$20.07M+35.0% | -$30.87M-959% | -$2.92M+69.9% | -$9.68M+17.7% | ||
| $7.25M-98.8% | $587.12M+3,536% | $16.15M0.0% | $16.15M0.0% | $16.15M0.0% | ||
| $394K-60.0% | $985K-31.4% | $1.44M+366% | $308K-80.2% | $1.55M+797% | ||
| $15.43M+1,692% | $861K-10.7% | $964K+125% | $428K-96.0% | $10.59M+3,697% | ||
| $0— | —— | —— | $7M+1,161% | $555K— | ||
| -$21.34M+2.2% | -$21.82M-47.3% | -$14.82M+69.4% | -$48.37M-91.7% | -$25.24M+38.9% | ||
| $37.4M-53.9% | $81.16M+148% | $32.75M+54.8% | $21.15M+3.3% | $20.48M— | ||
| $22.11M+89.1% | $11.69M-45.7% | $21.53M+55.5% | $13.85M-36.2% | $21.69M+42.5% | ||
| $44K-99.6% | $12.28M-20.7% | $15.49M-48.1% | $29.82M+1,114% | $2.46M+295% | ||
| $178K-29.9% | $254K+10.4% | $230K-12.9% | $264K-18.5% | $324K-13.8% | ||
| $819K-35.8% | $1.28M-5.0% | $1.34M-0.9% | $1.36M-0.9% | $1.37M-4.0% | ||
| $55.47M— | —— | —— | —— | $55.47M0.0% | ||
| $0+100% | -$19K0.0% | -$19K+94.7% | -$358K+54.5% | -$786K+73.0% | ||
| $463K-49.8% | $923K-10.6% | $1.03M-9.0% | $1.14M+4.0% | $1.09M+4.8% | ||
| -$575K-107% | $8.66M+256% | $2.43M+129% | -$8.39M-5,693% | $150K— | ||
| -$4.13M-150% | $8.19M+138% | -$21.34M-297% | $10.85M+5.6% | $10.27M+427% | ||
| $71K— | —— | —— | $1.11M+21.6% | $909K— | ||
| -$91K— | —— | $503K+1,777% | -$30K0.0% | -$30K-11.1% | ||
| $947K— | —— | $857K— | —— | $506K— | ||
| $7.25M-98.8% | $587.12M+3,536% | $16.15M0.0% | $16.15M0.0% | $16.15M0.0% | ||
| $207K+4,040% | $5K-97.4% | $190K+53.2% | $124K— | $0-100% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$167K0.0% | -$167K— | —— | —— | $0— | ||
| $0— | —— | —— | $7M+1,161% | $555K— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $44K-99.6% | $12.28M-20.7% | $15.49M-48.1% | $29.82M+1,114% | $2.46M+295% | ||
| $56.84M-53.5% | $122.36M+56.4% | $78.25M+8.1% | $72.37M+32.6% | $54.6M-35.1% | ||
| $56.84M-53.5% | $122.36M+56.4% | $78.25M+8.1% | $72.37M+32.6% | $54.6M-35.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Collegium Pharmaceutical, Inc. generate?
- Collegium Pharmaceutical, Inc. (COLL) generated $331.0M in operating cash flow over the trailing twelve months.
- What is Collegium Pharmaceutical, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Collegium Pharmaceutical, Inc.'s free cash flow was $329.8M over the trailing twelve months, up 60.3% year over year.
- Where does Collegium Pharmaceutical, Inc.'s cash flow data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
